As global regulatory expectations evolve, biotech sponsors face growing pressure to make smarter, earlier decisions about where and how to run their trials.

In this episode, Novotech experts Renita Hite (Director of Regulatory Affairs, Drug Development Consulting) and Scott Schliebner (Global Head of Drug Development Consulting) join moderator Meredith Landry to discuss how early-stage sponsors can adapt to shifting FDA initiatives, accelerated global pathways, and increasing demands for regulatory flexibility.

They explore:

How new FDA initiatives—like AI-driven reviews, user fee changes, and the National Priority Voucher—are reshaping IND strategy

Why sponsors should design trials with global data packages in mind from day one

Accelerated and early access pathways that can speed startup and market entry

How CROs are evolving to help sponsors prioritize markets and build regulatory flexibility

If you’re planning trials for 2025 and beyond, this conversation will help you prepare for what’s next—and position your program for long-term success.

About This Episode

This episode is the final installment (4 of 4) in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development.

Catch up on earlier episodes:

[Part 1: Navigating Regulatory Changes & Market Dynamics]

[Part 2: Navigating Regulatory & Market Shifts]

[Part 3: Navigating Regulatory Changes & Market Dynamics]